Direkt zum Inhalt
Merck
  • [Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].

[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].

No to hattatsu = Brain and development (2013-04-19)
Tae Ikeda, Kuriko Kagitani-Shimono, Yoshiko Iwatani, Yukihiro Kitai, Masaya Tachibana, Koji Tominaga, Takeshi Okinaga, Toshisaburo Nagai, Keiichi Ozono
ZUSAMMENFASSUNG

We report a case of a 15-year-old girl with relapsing-remitting multiple sclerosis (MS) who received cyclophosphamide pulse therapy. At the age of 5 years, she displayed symptoms such as headache and unconsciousness after varicella infection as the first episode of MS. She had been treated with methylprednisolone pulse therapy, intravenous immunoglobulin, interferon-beta1b, and azathioprine. However, she had relapsed 12 times by the age of 15 years. At this time, she showed weakness and severe paralysis of her left leg, and even 1 month after methylprednisolone pulse therapy, she still had gait impairment and showed gadolinium-enhanced lesion on brain magnetic resonance imaging. We then started cyclophosphamide pulse therapy (600 mg/m2) once a month for 12 months combined with interferon-beta1a. She had no serious side effects and she could walk again after 4 months on cyclophosphamide treatment. She has been free from relapse for 2 years and 8 months until the present time. Although only a few studies have indicated the efficacy of cyclophosphamide pulse therapy for childhood MS, we consider careful use of cyclophosphamide could be one of the options for refractory childhood MS.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Interferon β-1a, European Pharmacopoeia (EP) Reference Standard